TRIREME GETS CE MARKING FOR GLIDER DILATION CATHETER.
The Glider(TM) is a first-in-class balloon dilatation catheter with a torquable shaft and novel tip design. These features permit the Glider(TM) to cross through tight lesions and stent struts. In addition, its unique balloon characteristics were designed to allow full dilatation of the side branch ostium and reduce the risk of dissections and side branch injuries.
"Conventional balloon catheters are not optimized to cross into side branches or to fully treat the ostium of the side branch. The unique characteristics of the Glider(TM) are designed to overcome these limitations," said Professor Carlo Di Mario from the Royal Brompton Hospital in London. "I am pleased to be working with TriReme as they develop products specifically tailored for the treatment of bifurcation disease."
"The Glider(TM) dilatation catheter follows the success of our Antares stent system and is another important product in TriReme's toolbox enabling treatment of a broad range of bifurcation lesions," said Eitan Konstantino, Ph.D., president and Chief Executive Officer of TMI. "We are committed to developing a series of innovative products that will enable the best possible treatment for patients suffering from complex arterial disease."
About Bifurcation Disease
Approximately 20% of all atherosclerosis cases involve lesions at or near side branches in the coronary tree. Acute and long term outcomes in this subset of patients are worse than the outcomes of patients with simple lesions. Moreover, when percutaneously treating bifurcation lesions, interventional cardiologists use a variety of complex techniques that involve the modification and distortion of tubular stents designed for straight rather than branching arteries. To date in the US, no stents are approved for use in bifurcations. For these reasons, bifurcation lesions are common reasons for referral to coronary bypass surgery.
About TriReme Medical, Inc.
TriReme Medical, Inc. (TMI) is a privately held medical device company. TMI is based in California and dedicated to the development and manufacturing of novel stent technology and other devices for the treatment of atherosclerotic disease at or near bifurcations.
In April 2009, TriReme received CE mark for its Antares SX stent system. Antares is a main vessel stent that is designed to adapt to a broad variety of bifurcation lesions and coronary anatomies to produce predictable results during provisional stenting. To date, Antares has been used in over 100 patients in Europe.
For more information, call 925/931-1300 or visit http://www.trirememedical.com.
|Printer friendly Cite/link Email Feedback|
|Publication:||Biotech Equipment Update|
|Date:||Sep 1, 2009|
|Previous Article:||LUTONIX REPORTS PATIENT ENROLLMENT IN 3 CLINICAL TRIALS.|
|Next Article:||PRESCIENT GETS PR0DUCT INNOVATION OF YEAR AWARD.|